Key result
Concurrent linezolid and SSRI use linked to serotonin syndrome and myelosuppression in two transplant cases.
Why the study?
The risks of serotonin syndrome and myelosuppression with concurrent use of linezolid and SSRIs in bone marrow transplant recipients are concerning and require clarification.
Population
2 bone marrow transplant recipients
Comparison
Linezolid combined with SSRI vs no combination
Design
Case report
Authors
Loading...
Suggests caution with linezolid and SSRIs in bone marrow transplant recipients; hypothesis-generating and requires prospective confirmation.
Case Report (n=2)
Concurrent use of linezolid and SSRIs should be avoided in bone marrow transplant recipients due to the risk of serotonin syndrome and myelosuppression.
Hachem et al. (2003) conducted a case report in Bone marrow transplant recipients (n=2). Concurrent use of linezolid and selective serotonin reuptake inhibitors (SSRIs) was evaluated on Serotonin syndrome and myelosuppression. Concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients was associated with serotonin syndrome and myelosuppression in two reported cases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: